Eli Lilly has confirmed its plan to acquire Ventyx Biosciences in a significant all-cash deal valued at $1.2 billion. This acquisition marks a strategic move for Lilly as it expands its portfolio beyond blockbuster obesity treatments into the realm of oral therapies aimed at inflammatory-mediated diseases. The agreement comes at a price of $14 per share for all outstanding shares of Ventyx, leading to a notable surge in Ventyx’s stock price amidst acquisition speculation. The deal is expected to enhance Lilly’s capabilities in developing innovative treatments within the autoimmune field.